Bone Therapeutics announced positive efficacy results for the 2nd patient cohort in its Phase I/IIA trial of ALLOB® allogeneic bone cell therapy product for the treatment of delayed-union fractures. Of eight patients treated, seven met primary endpoints of the trial within 6-month follow-up.
The ongoing Phase I/IIA study is a 6-month open-label trial to evaluate safety and efficacy of ALLOB in the treatment of delayed-union fractures of long bones.
This 8-patient cohort yielded radiological scores with a statistically significant improvement (77%) at 6 months. Overall, pain at the fracture site improved by 68% and health status by 50% at 6 months, also statistically significant levels.
Bone Therapeutics announced positive efficacy results for the 2nd patient cohort in its Phase I/IIA trial of ALLOB® allogeneic bone cell therapy product for the treatment of delayed-union fractures. Of eight patients treated, seven met primary endpoints of the trial within 6-month follow-up.
Bone Therapeutics announced positive efficacy results for the 2nd patient cohort in its Phase I/IIA trial of ALLOB® allogeneic bone cell therapy product for the treatment of delayed-union fractures. Of eight patients treated, seven met primary endpoints of the trial within 6-month follow-up.
The ongoing Phase I/IIA study is a 6-month open-label trial to evaluate safety and efficacy of ALLOB in the treatment of delayed-union fractures of long bones.
This 8-patient cohort yielded radiological scores with a statistically significant improvement (77%) at 6 months. Overall, pain at the fracture site improved by 68% and health status by 50% at 6 months, also statistically significant levels.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
